%PDF-1.4
%
39 0 obj
<>
endobj
36 0 obj
<>
endobj
92 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-10-06T19:55Z
2024-03-28T18:57:24-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T18:57:24-07:00
application/pdf
Heather
2002-890.nov
uuid:2c1c3865-1dd2-11b2-0a00-c909275dc400
uuid:2c1c3867-1dd2-11b2-0a00-810000000000
endstream
endobj
25 0 obj
<>
endobj
26 0 obj
<>
endobj
40 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 13 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 15 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 17 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 19 0 R/Type/Page>>
endobj
106 0 obj
[110 0 R]
endobj
107 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 10 0 0 10 54 713.1616 Tm
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
-0.02721 Tw 8 0 0 8 54 703.1616 Tm
[(W)79.9 (e wish to thank Professor Matthew Liang, MD for his valuable comments)]TJ
0.02499 Tw 0 -1.25 TD
(on the manuscript.)Tj
/T1_0 1 Tf
0 Tw 10 0 0 10 54 669.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 659.1616 Tm
[(1.)-875.1 (ACR Subcommittee on RA)-220.2 (Guidelines. Guidelines for the )]TJ
1.675 -1.25 Td
[(management of rheumatoid arthritis, 2002 update. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2002;46:328-46.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Furst DE, Keystone EC, Breedveld FC, et al. Updated consensus)]TJ
1.675 -1.25 Td
(statement on tumour necrosis factor blocking agents for the)Tj
T*
(treatment of rheumatoid arthritis and other rheumatic diseases)Tj
0 Tc T*
[(\(April 2001\). )54.8 (Ann Rheum Dis 2001;60 Suppl 3:2-5.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Emery P)110.7 (, Reginster JY)128.8 (, )54.8 (Appelboom )17.7 (T)74 (, et al. )17.7 (WHO collaborating)]TJ
1.675 -1.25 Td
(centre consensus meeting on anti-cytokine therapy in rheumatoid)Tj
T*
(arthritis. Rheumatology 2001;40:699-702.)Tj
-1.675 -1.25 Td
[(4.)-875.1 (Keystone EC. )17.7 (T)35 (umor necrosis factor)19.7 (-alpha blockade in the )]TJ
1.675 -1.25 Td
[(treatment of rheumatoid arthritis. Rheum Dis Clin North )54.8 (Am)]TJ
0 Tc 0 Tw T*
(2001;27:427-43.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(5.)-875.1 (Moreland L)73.9 (W)91.8 (, Schif)17.7 (f MH, Baumgartner SW)91.7 (, et al. Etanercept)]TJ
1.675 -1.25 Td
[(therapy in rheumatoid arthritis. )54.8 (A)-220.1 (randomized, controlled trial. )54.8 (Ann)]TJ
T*
(Intern Med 1999;130:478-86.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Bathon JM, Martin R)54.8 (W)91.9 (, Fleischmann RM, et al. )54.8 (A)-220.1 (comparison of)]TJ
1.675 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
T*
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (W)79.9 (einblatt ME, Kremer JM, Bankhurst )54.7 (AD, et al. )54.7 (A)-220.1 (trial of)]TJ
1.675 -1.25 Td
(etanercept, a recombinant tumor necrosis factor receptor:Fc fusion)Tj
T*
(protein in patients with rheumatoid arthritis receiving methotrexate.)Tj
0 Tc T*
(N Engl J Med 1999;340:253-9.)Tj
-0.00011 Tc 31.325 34.421 Td
[(8.)-875.1 (Lipsky PE, van der Heijde DM, St Clair EW)91.7 (, et al; )54.8 (Anti-T)34.8 (umor)]TJ
1.675 -1.25 Td
[(Necrosis Factor )17.7 (T)35 (rial in Rheumatoid )54.8 (Arthritis with Concomitant)]TJ
T*
(Therapy Study Group. Infliximab and methotrexate in the treatment)Tj
T*
(of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Cush JJ, Matteson EL. FDA)-165.2 (Advisory committee reviews safety of)]TJ
1.675 -1.25 Td
[(TNF inhibitors. Hotline )54.8 (American College of Rheumatology; Sept,)]TJ
0 Tc T*
[(2001 [cited June 13, 2003]. )54.8 (A)74 (vailable from: )]TJ
-0.00011 Tc 0 Tw T*
[(http://www)64.8 (.rheumatology)64.8 (.or)17.7 (g/research/hotline/0901tnf.html)]TJ
0.02499 Tw -2.175 -1.25 Td
[(10.)-875.1 (McInnes IB. Rheumatoid arthritis. From bench to bedside. Rheum)]TJ
2.175 -1.25 Td
[(Dis Clin North )54.8 (Am 2001;27:373-87.)]TJ
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Maini RN, )17.7 (T)69.9 (aylor PC, Plaeolog E, et al. )54.8 (Anti-tumour necrosis factor)]TJ
2.1381 -1.25 Td
(specific antibody \(infliximab\) treatment provides insights into the)Tj
T*
[(pathophysiology of rheumatoid arthritis. )54.8 (Ann Rheum Dis 1999;58)]TJ
T*
(Suppl 1:I56-60.)Tj
-2.175 -1.25 Td
[(12.)-875.1 (Sher)17.7 (gy )17.7 (WJ, Phillips Jr RM, Hunt RE, Hernandez J. Safety and )]TJ
2.175 -1.25 Td
[(ef)17.7 (ficacy of infliximab therapy after etanercept failure: a case series)]TJ
T*
[([abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl 9:S81.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (Y)99.8 (azici )36.8 (Y)128.9 (, Erkan D, Lef)17.7 (f L, Kulman I, Harrison MJ, Schwartzman S.)]TJ
2.175 -1.25 Td
[(Do etanercept \(ET)79.7 (A\) na\225ve patients respond better to infliximab)]TJ
T*
[(\(INF\) than RA)-220.2 (patients who have failed ET)79.7 (A? [abstract]. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44 Suppl 9:S81.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(14.)-875.1 (Kremer JM. Rational use of new and existing disease-modifying)]TJ
2.175 -1.25 Td
[(agents in rheumatoid arthritis. )54.8 (Ann Intern Med 2001;134:695-706.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Scallon B, Cai )54.8 (A, Solowski N, et al. Binding and functional)]TJ
2.175 -1.25 Td
(comparisons of two types of tumor necrosis factor antagonists. )Tj
T*
[(J Pharmacol Exp )17.7 (Ther 2002;301:418-26.)]TJ
ET
0 0 0 1 K
54 54 m
558 54 l
S
BT
/T1_2 1 Tf
8 0 0 8 420.9531 35.9844 Tm
[(The Journal of Rheumatology 2003; 30:1)73.9 (1)]TJ
0 Tc 0 Tw -45.8691 -0.0313 Td
(2318)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
19 0 obj
<>stream
8;Z\5d?;Ej#ikr7OPdTO2$$S+g?h)Z*LT[g<(`5PV1p1YZ='8XQEgJR?blC]9+l/U*+-l
Gu.f&3BaR:.C+,^58LYBl;n#Fa!4>;*hPLL
RC/9SPf7k,qU>3W!9rm]!!~>
endstream
endobj
23 0 obj
[/Indexed/DeviceRGB 255 22 0 R]
endobj
22 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
10 0 obj
<>
endobj
52 0 obj
<>
endobj
48 0 obj
<>
endobj
83 0 obj
<>
endobj
97 0 obj
<>
endobj
42 0 obj
<>
endobj
78 0 obj
<>stream
H{PSwrEy U->EB4H#! FQX_ҭN{nۍvt~3g~s93s>?pwݼ QP`<^,J|_ya7Ͱ|n8?⢃-֠?IVցgSAgqؙE-Z(IWHE)rv^+W|4]ήd$ B6\!Se즴D4]", reT(Jw"ʥIx>V*JB6`#P"eEf1-!uBi,::Hwل<"< Ͷ#!^ߞo#]݄\{)g|tS^Eѓ:ǟIΣ..W]7d62_nO_Z
,2W'n]j9S֟ڤ2TE &qA+Uiמu^tZ߀m?4-kϳlfwר,MF
SFq*MD袦&JͳfOSt"O "8OBFׄ <~eHV\\VE줆ܙ '0_sGc7f2JV.%`),-#/K#|ȦZY=Pj=N5Q뎣!;و0dD+Q2CEO gZz[O4gH0IYIB}RDȹXSg6KT%ª73MU^ƣ&zg
4)E[tYeC|`Mn N`YLN.'y
c@5P\("&CɃ;0NҪ~o\E C>?Dd
[7ҵ
2䘨R].*I3rO:X!(bЌͣ͜ ohh[k+(yu{nL>x]I
5tkɕ!?J)
F#"8Rrh_mv[qWw{ԝQ7h[9WYfiȎs_y7IN~Oq$]bnu#.o`ŕII͌m8i_9#LK4ZRw{;>wjaʼnKɧ)κ
]G{R.o&PpZ̊M#'W/IN8G^DtpƸpXخ|PQW-z̍w;{[P!gs6ϡ>qH|W
>nueCكӱWܜlvȽ='ˬ}}\;'3xtKbТ$zW2Qn:ceU'en?D8`߿e
O/_X邦YN9``ja
^㰰?ܞpf2gR
KuҺ? :9vh}e3Kuy+<`Z%L%U
UH N/o}-AQКm-Q38Nso*\^D]j
d:i@M
ze/Hʴ=87~tUuR^qQl"c;ҜbCکuSNqFs2e)3iF&ȔzuF~ !搑Hkߛ}W;{ML/2(Saߡ` '˼ZAMY1$ZzeAgZZߊQQjA@J!_` UJ춻Uj=eꮭos%ڎt$\l$Fɀr\}~5y'aVoܓC)\4o&hJKZ~FLm(}e>zf?Բh̅0`AQԧ{ WViL*4m Hi%{w߲͈\\쫧ZU(i3M@5I(')dg noheY13)X_@>|
X0 xEzIraHs*0|8oݾ}D